Cost-Effectiveness of Direct Non-Vitamin K Oral Anticoagulants Versus Vitamin K Antagonists for the Management of Patients with Non-Valvular Atrial Fibrillation Based on Available “Real-World” Evidence: The Italian National Health System Perspective
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost-Effectiveness of Direct Non-Vitamin K Oral Anticoagulants Versus Vitamin K Antagonists for the Management of Patients with Non-Valvular Atrial Fibrillation Based on Available “Real-World” Evidence: The Italian National Health System Perspective
Authors
Keywords
-
Journal
CLINICAL DRUG INVESTIGATION
Volume 41, Issue 3, Pages 255-267
Publisher
Springer Science and Business Media LLC
Online
2021-02-19
DOI
10.1007/s40261-021-01002-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparative stroke, bleeding, and mortality risks in older Medicare patients treated with oral anticoagulants for nonvalvular atrial fibrillation
- (2019) David J. Graham et al. AMERICAN JOURNAL OF MEDICINE
- Influence of Polypharmacy on the Effectiveness and Safety of Rivaroxaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation
- (2019) Brandon K. Martinez et al. PHARMACOTHERAPY
- Non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation patients with concomitant peripheral artery disease
- (2019) Hsin-Fu Lee et al. European Heart Journal-Cardiovascular Pharmacotherapy
- Effectiveness and safety of rivaroxaban vs warfarin in people with non-valvular atrial fibrillation and diabetes: an administrative claims database analysis
- (2018) C. I. Coleman et al. DIABETIC MEDICINE
- Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach
- (2018) Xiaoyan Li et al. PLoS One
- Effectiveness and Safety of Non–Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon: Data from 61,000 Patients with Atrial Fibrillation
- (2018) Edin Basic et al. THROMBOSIS AND HAEMOSTASIS
- Dabigatran, rivaroxaban and apixaban vs. high TTR warfarin in atrial fibrillation
- (2018) Sara Själander et al. THROMBOSIS RESEARCH
- Effectiveness and Safety of Different Rivaroxaban Dosage Regimens in Patients with Non-Valvular Atrial Fibrillation: A Nationwide, Population-Based Cohort Study
- (2018) Hsin-Yi Huang et al. Scientific Reports
- Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care
- (2018) Yana Vinogradova et al. BMJ-British Medical Journal
- Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care
- (2018) Yana Vinogradova et al. BMJ-British Medical Journal
- Safety and Effectiveness of Direct Oral Anticoagulants Versus Vitamin K Antagonists: Pilot Implementation of a Near‐Real‐Time Monitoring Program in Italy
- (2018) Flavia Mayer et al. Journal of the American Heart Association
- Patient characteristics and bleeding events in nonvalvular atrial fibrillation patients treated with apixaban or vitamin K antagonists: real-world evidence from Italian administrative databases
- (2018) Sreeram Ramagopalan et al. Journal of Comparative Effectiveness Research
- Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients
- (2018) Gregory Y.H. Lip et al. STROKE
- Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study
- (2017) Tomas Forslund et al. EUROPACE
- 2017 ESC/EACTS Guidelines for the management of valvular heart disease
- (2017) Helmut Baumgartner et al. EUROPEAN HEART JOURNAL
- Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis
- (2017) Jonathan AC Sterne et al. HEALTH TECHNOLOGY ASSESSMENT
- Comparative effectiveness of dabigatran and rivaroxaban versus warfarin for the treatment of non-valvular atrial fibrillation
- (2017) Lindsay G.S. Bengtson et al. Journal of Cardiology
- Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies
- (2017) Amr Makady et al. PHARMACOECONOMICS
- 2016 ESC GUIDELINES FOR THE MANAGEMENT OF ATRIAL FIBRILLATION DEVELOPEDIN COLLABORATION WITH EACTS
- (2017) Paulus Kirchhof et al. RUSSIAN JOURNAL OF CARDIOLOGY
- Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice
- (2017) Steve Deitelzweig et al. THROMBOSIS AND HAEMOSTASIS
- Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis
- (2017) José A López-López et al. BMJ-British Medical Journal
- Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis
- (2017) José A López-López et al. BMJ-British Medical Journal
- Major Bleeding Complications and Persistence With Oral Anticoagulation in Non‐Valvular Atrial Fibrillation: Contemporary Findings in Real‐Life Danish Patients
- (2017) Morten Lamberts et al. Journal of the American Heart Association
- Cost-Effectiveness of Dabigatran (150 mg Twice Daily) and Warfarin in Patients ≥65 Years With Nonvalvular Atrial Fibrillation
- (2016) Brian M. Salata et al. AMERICAN JOURNAL OF CARDIOLOGY
- A Comparison of Dabigatran With Warfarin for Stroke Prevention in Atrial Fibrillation in an Asian Population
- (2016) Lok Bin Yap et al. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS
- Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study
- (2016) Craig I. Coleman et al. CURRENT MEDICAL RESEARCH AND OPINION
- Effectiveness and safety of dabigatran versus acenocoumarol in ‘real-world’ patients with atrial fibrillation
- (2016) Jennie Korenstra et al. EUROPACE
- Bleeding in patients with atrial fibrillation treated with dabigatran, rivaroxaban or warfarin: A retrospective population-based cohort study
- (2016) Martin H. Ellis et al. European Journal of Internal Medicine
- A real world data of dabigatran etexilate: multicenter registry of oral anticoagulants in nonvalvular atrial fibrillation
- (2016) Bunyamin Yavuz et al. JOURNAL OF THROMBOSIS AND THROMBOLYSIS
- Anticoagulation Use and Clinical Outcomes After Major Bleeding on Dabigatran or Warfarin in Atrial Fibrillation
- (2016) Inmaculada Hernandez et al. STROKE
- “Unreal world” or “real world” data in oral anticoagulant treatment of atrial fibrillation
- (2016) Gregory Y. H. Lip et al. THROMBOSIS AND HAEMOSTASIS
- Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study
- (2016) Torben Bjerregaard Larsen et al. BMJ-British Medical Journal
- Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study
- (2016) Torben Bjerregaard Larsen et al. BMJ-British Medical Journal
- Cost-Effectiveness of Apixaban versus Warfarin in Chinese Patients with Non-Valvular Atrial Fibrillation: A Real-Life and Modelling Analyses
- (2016) Xue Li et al. PLoS One
- Comparison of the Short-Term Risk of Bleeding and Arterial Thromboembolic Events in Nonvalvular Atrial Fibrillation Patients Newly Treated With Dabigatran or Rivaroxaban Versus Vitamin K AntagonistsCLINICAL PERSPECTIVES
- (2015) Géric Maura et al. CIRCULATION
- A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system
- (2015) Janet Schnee et al. THROMBOSIS AND HAEMOSTASIS
- Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation
- (2015) Katsiaryna Bykov et al. THROMBOSIS AND HAEMOSTASIS
- Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study
- (2015) N. S. Abraham et al. BMJ-British Medical Journal
- Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study
- (2015) N. S. Abraham et al. BMJ-British Medical Journal
- New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events
- (2015) Agon Mekaj et al. Therapeutics and Clinical Risk Management
- Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study
- (2015) Kim Bouillon et al. Lancet Haematology
- Efficacy and Cost-Effectiveness of Dabigatran Etexilate Versus Warfarin in Atrial Fibrillation in Different Age Subgroups
- (2014) Andreas Clemens et al. AMERICAN JOURNAL OF CARDIOLOGY
- Bleeding Rates in Veterans Affairs Patients with Atrial Fibrillation Who Switch from Warfarin to Dabigatran
- (2014) Mary S. Vaughan Sarrazin et al. AMERICAN JOURNAL OF MEDICINE
- Dabigatran and Warfarin for Secondary Prevention of Stroke in Atrial Fibrillation Patients: A Nationwide Cohort Study
- (2014) Torben Bjerregaard Larsen et al. AMERICAN JOURNAL OF MEDICINE
- Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients
- (2014) François Laliberté et al. CURRENT MEDICAL RESEARCH AND OPINION
- Prognosis and treatment of atrial fibrillation patients by European cardiologists: One Year Follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry)
- (2014) Gregory Y.H. Lip et al. EUROPEAN HEART JOURNAL
- Global epidemiology of atrial fibrillation
- (2014) Faisal Rahman et al. Nature Reviews Cardiology
- Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
- (2014) Torbjørn Wisløff et al. PHARMACOECONOMICS
- Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel
- (2014) Raffaele de Caterina et al. THROMBOSIS AND HAEMOSTASIS
- Worldwide Epidemiology of Atrial Fibrillation
- (2013) Sumeet S. Chugh et al. CIRCULATION
- Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events—European Registry in Atrial Fibrillation (PREFER in AF)
- (2013) Paulus Kirchhof et al. EUROPACE
- Efficacy and Safety of Dabigatran Etexilate and Warfarin in “Real-World” Patients With Atrial Fibrillation
- (2013) Torben Bjerregaard Larsen et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
- (2013) Christian T Ruff et al. LANCET
- Cost-Effectiveness of Rivaroxaban Versus Warfarin for Stroke Prevention in Atrial Fibrillation in the Belgian Healthcare Setting
- (2013) Joris Kleintjens et al. PHARMACOECONOMICS
- Incidence and costs of hip fractures vs strokes and acute myocardial infarction in Italy: comparative analysis based on national hospitalization records
- (2012) Prisco Piscitelli et al. Clinical Interventions in Aging
- Apixaban versus Warfarin in Patients with Atrial Fibrillation
- (2011) Christopher B. Granger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
- (2011) Manesh R. Patel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of the type of centre on management of AF patients: Surprising evidence for differences in antithrombotic therapy decisions
- (2011) Andrea Gerth et al. THROMBOSIS AND HAEMOSTASIS
- Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: A tutorial
- (2010) Beth S Woods et al. BMC Medical Research Methodology
- The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
- (2009) Alessandro Liberati et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Dabigatran versus Warfarin in Patients with Atrial Fibrillation
- (2009) Stuart J. Connolly et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search